Characteristics of 798 female first-degree relatives with either factor V Leiden, prothrombin G20210A, or a combination of these defects, including homozygosity
| . | All female relatives . | ||
|---|---|---|---|
| No defects . | Single defects . | Combined defects* . | |
| Female relatives, n | 497 | 251 | 50 |
| Follow-up, y† | 32 (0.1-35) | 28 (0.1-35) | 24 (2-35) |
| Factor V Leiden (%) | NA | 160 (64) | 46 (92) |
| Prothrombin G20210A (%) | NA | 91 (36) | 39 (81) |
| Ever COC users, n (%) | 366 (74) | 171 (68) | 34 (68) |
| Age at start of COC, y | 19 (15-47) | 20 (15-49) | 19 (15-49) |
| Duration of COC use, y | 8 (0.1-30) | 6 (0.1-27) | 6 (0.5-16) |
| Ever pregnant, n (%) | 364 (73) | 175 (70) | 36 (72) |
| Age at first pregnancy | 24 (15-41) | 24 (15-36) | 23 (17-38) |
| Number of pregnancies, n | 2 (1-10) | 3 (1-10) | 2 (1-7) |
| Total pregnancy time, y | 2 (0.3-9) | 3 (0.3-9) | 2 (0.8-6) |
| Age at time of VTE, y | 31 (18-46) | 34 (17-48) | 26 (17-39) |
| VTE, n† | 17 | 22 | 11 |
| Unprovoked, n | 1 | 4 | 1 |
| Provoked, n | |||
| COC use | 4 | 1 | 2 |
| Pregnancy/postpartum | 5 | 9 | 7 |
| COC use + postpartum | 2 | 1 | 0 |
| COC use + other risk factor | 0 | 4 | 0 |
| Major trauma, surgery, immobilization | 5 | 3 | 1 |
| . | All female relatives . | ||
|---|---|---|---|
| No defects . | Single defects . | Combined defects* . | |
| Female relatives, n | 497 | 251 | 50 |
| Follow-up, y† | 32 (0.1-35) | 28 (0.1-35) | 24 (2-35) |
| Factor V Leiden (%) | NA | 160 (64) | 46 (92) |
| Prothrombin G20210A (%) | NA | 91 (36) | 39 (81) |
| Ever COC users, n (%) | 366 (74) | 171 (68) | 34 (68) |
| Age at start of COC, y | 19 (15-47) | 20 (15-49) | 19 (15-49) |
| Duration of COC use, y | 8 (0.1-30) | 6 (0.1-27) | 6 (0.5-16) |
| Ever pregnant, n (%) | 364 (73) | 175 (70) | 36 (72) |
| Age at first pregnancy | 24 (15-41) | 24 (15-36) | 23 (17-38) |
| Number of pregnancies, n | 2 (1-10) | 3 (1-10) | 2 (1-7) |
| Total pregnancy time, y | 2 (0.3-9) | 3 (0.3-9) | 2 (0.8-6) |
| Age at time of VTE, y | 31 (18-46) | 34 (17-48) | 26 (17-39) |
| VTE, n† | 17 | 22 | 11 |
| Unprovoked, n | 1 | 4 | 1 |
| Provoked, n | |||
| COC use | 4 | 1 | 2 |
| Pregnancy/postpartum | 5 | 9 | 7 |
| COC use + postpartum | 2 | 1 | 0 |
| COC use + other risk factor | 0 | 4 | 0 |
| Major trauma, surgery, immobilization | 5 | 3 | 1 |
High factor VIII level was present in 8 (22%), 99 (39%), and 197 (40%) women with combined defects, single defects, and no defects, respectively (in 14 women factor VIII levels were not available). Data are given as median (min − max) unless otherwise indicated.
COC indicates combined oral contraceptive; NA, data not applicable; and VTE, venous thromboembolism.
Including 14 homozygote carriers of factor V Leiden, of whom 3 were also heterozygous for prothrombin G20210A, and 4 homozygote carriers of the prothrombin G20210A mutation, respectively.
Restricted to those aged 15-50 years.